Trial Profile

Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lasmiditan (Primary)
Indications Migraine
Focus Registrational; Therapeutic Use
Acronyms CENTURION
Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd

Most Recent Events

24 Mar 2023 Results from the open-label extension of the CENTURION randomized trial published in the Cephalalgia
10 Dec 2022 Results from the open label extension evaluating dose optimization, patterns of use, migraine-related disability, and quality of life during lasmiditan treatment, presented at the 16th European headache federation COngress
17 Sep 2022 Results (n=208) of post hoc analysis of randomized controlled phase 3 CENTURION Trial assessing the safety profile of lasmiditan in the Chinese population published in the Advances in Therapy

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com